Evidence map›Paper›PMID 34466001›Full record

ArticleOncoTargets and therapy2021

Simultaneous Follicular Lymphoma and Myelofibrosis: Report of a Case with Review of the Literature.

Ling-Zhijie Kong, Jing Li, Rui-Cang Wang, Lin Kang, Qiang Wei, Yan Li

Open access · goldAbstract readCase Reports
In one paragraph

Article in OncoTargets and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Exploring the molecular mechanisms between lymphoma and myelofibrosis.American journal of translational research · 2024
    Review
  3. American journal of nuclear medicine and molecular imaging · 2024
    Article
  4. Brucellosis complicated by myelofibrosis: report of five cases and review of literature.International journal of clinical and experimental pathology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ling-Zhijie KongDepartment of Haematology, Hebei General Hospital, Shijiazhuang, Hebei, People's Republic of China.ORCID 0000-0002-5397-7937
Jing LiDepartment of Hematology, Hebei Province Hospital of Chinese Medicine, Shijiazhuang, Hebei, People's Republic of China.
Rui-Cang WangDepartment of Haematology, Hebei General Hospital, Shijiazhuang, Hebei, People's Republic of China.
Lin KangDepartment of Pathology, Hebei General Hospital, Shijiazhuang, Hebei, People's Republic of China.
Qiang WeiDepartment of Nuclear Medicine, Hebei General Hospital, Shijiazhuang, Hebei, People's Republic of China.
Yan LiDepartment of Haematology, Hebei General Hospital, Shijiazhuang, Hebei, People's Republic of China.
Hebei General Hospital · CNHebei North University · CNHospital of Hebei Province · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMyelofibrosis (MF) is often associated with chronic myeloid leukemia, myelodysplastic syndrome and primary myeloproliferative neoplasms (MPN), but few number cases of malignant lymphoma with myelofibrosis was reported, and a few cases about follicular lymphoma with MF were found. Here we described a case of follicular lymphoma (FL) complicated by myelofibrosis. CASE PRESENTATION: A 43-year-old man was diagnosed with follicular lymphoma (FL) complicated by MF, besides, the lymphoma staging of this patient was AnnArbor IV B. The cytokines of plated-derived growth factor (PDGF), basic fibroblast growth factor (b-FGF), vascular endothelial growth factor (VEGF), tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), interleukin-2 (IL-2), and transforming growth factor-β (TGF-β) were positive, while JAK2V617F, MPL, and CALR mutations were negative. After first course of chemotherapy, the peripheral blood and MF improved. The systemic superficial lymph nodes and spleen were significantly narrowed after the third cycle of chemotherapy.

conclusionThe production of various cytokines, such as b-FGF, TNF-α, TGF-β, PDGF, IL-1β, IL-2, IL-6, IL-10, may contribute to the development of MF.

Indexed as

cytokinesfollicular lymphomaimmunohistochemistrymyelofibrosis

Identifiers

PMID34466001
PMCPMC8403076
OpenAlexW3195991953

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.